SCHEMBL4023218

SCHEMBL4023218

NCCCCCCOc1ccc(CN2CCOCC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.65
SMN1; SMN2 Q16637 2/20 0.57
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
TP53 P04637 3/20 0.53
HPGD P15428 2/20 0.53
TSHR P16473 2/20 0.51
ALDH1A1 P00352 1/20 0.51
CYP1A2 P05177 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM1 P11229 1/20 0.51
HTR2A P28223 1/20 0.51
MAPK1 P28482 1/20 0.51
SCN1A P35498 1/20 0.51
HTR2B P41595 1/20 0.51
KCNH2 Q12809 1/20 0.51
SCN2A Q99250 1/20 0.51
SIGMAR1 Q99720 1/20 0.51
SCN3A Q9NY46 1/20 0.51
ACHE P22303 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27661537 0.86 HRH3 (0.65) HRH3SMN1; SMN2NPC1RAB9ATP53
SCHEMBL4026244 0.85 CA12 (0.62) HRH3NPC1RAB9ATSHRALDH1A1
SCHEMBL27640973 0.84 HRH3 (0.67) HRH3SMN1; SMN2NPC1RAB9ATP53
SCHEMBL10917631 0.84 HRH3 (0.72) HRH3TSHRACHERAD52
SCHEMBL16702209 0.82 HRH3 (0.68) HRH3SMN1; SMN2TSHRALDH1A1CYP1A2
Hydrochloric Acid SCHEMBL16702258 0.81 HRH3 (0.67) HRH3SMN1; SMN2NPC1RAB9ATP53
SCHEMBL874183 0.81 LTA4H (0.61) HRH3NPC1RAB9ATSHRALDH1A1
SCHEMBL10661541 0.79 HRH3 (0.74) HRH3TSHRACHERAD52
SCHEMBL3570492 0.79 HRH3 (1.00) HRH3ACHERAD52
SCHEMBL3569242 0.79 HRH3 (1.00) HRH3ACHERAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450348-B2 Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects FORMA TM, LLC (US) 2013-05-28 US disclosed
US-8450348-B2 Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects FORMA TM, LLC (US) 2013-05-28 US disclosed
US-8450348-B2 Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects FORMA TM, LLC (US) 2013-05-28 US disclosed
EP-2096107-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2009-09-02 EP disclosed
EP-2096107-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2009-09-02 EP disclosed
EP-1674457-B1 Derivatives of squaric acid with anti-proliferative activity GPC BIOTECH AG (DE) 2009-06-03 EP disclosed
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity Valo Health, LLC 2008-08-21 US disclosed
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity Valo Health, LLC 2008-08-21 US disclosed
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity Valo Health, LLC 2008-08-21 US disclosed
EP-1674457-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2006-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity SQLE, FDFT1, DLD HRH3 3983/4885SMN1; SMN2 528/4885NPC1 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.